Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

201 to 225 of 336 results

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

The solution for Spanish pharma companies lies abroad

13-03-2013

The pressure on the prices of medicines by Spanish government has seen the pharmaceutical market in Spain…

AlmirallEuropeFinancialGrifolsPharmaceuticalPricingRegulationZeltia

Unnecessary drug regulations hiking Rx prices in USA: NCPA Study

08-03-2013

As drug coverage increases as a result of expanded health insurance and Medicaid coverage under the USA's…

BiotechnologyNorth AmericaPharmaceuticalPricingRegulation

NICE makes U-turn, recommending Novartis' Xolair for children aged six-11 years

07-03-2013

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has today (March 7)…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

UK's NICE backs use of Novartis' Lucentis for diabetic macular edema

27-02-2013

Reversing an earlier negative opinion, in a final guidance issued today (February 27), the UK drugs watchdog…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

NICE draft guidance rejects Eli Lilly's Alimta for NSCLC maintenance

22-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft…

AlimtaEli LillyEuropeOncologyPharmaceuticalPricingRegulation

UK's NICE says no to Novartis' Jakavi for myelofibrosis in draft guidance

13-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today (February…

EuropeJakaviNovartisOncologyPharmaceuticalPricingRegulation

MEPS vote for access to cheaper generics drugs in Europe; mixed industry reaction

07-02-2013

European patients should have quicker access to cheaper "generic" medicines, according to Members of…

EuropeGenericsLegalPharmaceuticalPricingRegulation

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga

01-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

UK treatment decisions seriously flawed and must not be used in Europe, say researchers

24-01-2013

The Quality Adjusted Life Years (QALY) approach to deciding what medical treatments are available on…

BiotechnologyEuropePharmaceuticalPricingRegulation

Scottish Medicines Consortium backs AstraZeneca/B-MS' Forxiga for type 2 diabetes

14-01-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and partner Bristol-Myers Squibb (NYSE: BMY) of the USA…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Russian government may stop foreign drugmakers from state tendering

10-01-2013

The Russian government is considering imposing a ban on the participation of foreign drug producers in…

EuropePharmaceuticalPoliticsPricingProductionRegulation

Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG

10-01-2013

The drug aclidinium bromide, trade names Eklira, Bretaris from Spain's largest drugmaker Almirall (ALM:…

aclidiniumAlmirallBretaris GenuairEkliraEuropePharmaceuticalPricingRegulationRespiratory and Pulmonary

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

09-01-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit…

BayerEuropeInlytaNexavarOncologyPfizerPharmaceuticalPricingRegulation

UK's NICE final guidance on Novartis' Lucentis for diabetic macular edema positive

03-01-2013

In final draft guidance issued today (4 January), the UK's drug watchdog the National Institute for Health…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Danish pharma agrees cap on medicine prices for the coming three years

03-01-2013

A three year price-cap agreement on medicine prices has been signed by Denmark's Minister of Health and…

EuropePharmaceuticalPricingRegulation

More transparency on medicine pricing called for by EU parliamentarians

19-12-2012

More transparency and precise time limits for decision-making on pricing and reimbursement of medicines…

EuropeGenericsPharmaceuticalPricingRegulation

Eisai disagrees with Germany's IQWiG report on epilepsy drug Fycompa

19-12-2012

In the assessment report by the German Institute for Quality and Efficiency in Health Care (IQWiG) on…

EisaiEuropeFycompaNeurologicalPharmaceuticalPricingRegulation

Australian review finds more work needed on new anticoagulants

19-12-2012

A report into anticoagulation therapies released yesterday by Australian Minister for Health Tanya Plibersek…

Asia-PacificBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulation

UK's NICE says Roche's Avastin not cost effective for advanced ovarian cancer

18-12-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

201 to 225 of 336 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top